Interleukin-1-alpha - Dainippon Sumitomo Pharma/Roche

Drug Profile

Interleukin-1-alpha - Dainippon Sumitomo Pharma/Roche

Alternative Names: Interleukin-1-alpha - Dainippon Sumitomo Pharma; rIL-1 alpha

Latest Information Update: 29 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Dainippon Sumitomo Pharma; National Cancer Institute (USA)
  • Class Interleukins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Interleukin 1-alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 05 Jun 2001 Discontinued-Clinical for Malignant melanoma in Japan (Intralesional)
  • 05 Jun 2001 Discontinued-Clinical for Non-small cell lung cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top